Cat.No. : CSC-RO0131 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0131 |
| Description | Ba/F3-EGFR-DEL19/T790M cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR) with DEL19 and T790M mutations. |
| Target Gene | EGFR |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
About 15 to 30 percent of lung cancer patients have EGFR gene mutations; significant mutations like del19 are very susceptible to EGFR tyrosine kinase inhibitors (TKIs). The scientists looked at a case containing an EGFR-L747P mutation, first misdiagnosed as del19. Their study employed advanced molecular dynamics simulations and binding free energy calculations to reveal how the L747P mutation stabilizes the active EGFR conformation, complicating its response to TKIs. This highlights the pressing need for innovative therapies targeting these less common mutations. In their work, the researchers established Ba/F3 cells expressing the EGFR-L747P mutation, demonstrating its oncogenic potential by enabling IL-3 independent growth. They evaluated the sensitivity of these cells to various EGFR-TKIs, revealing that while the L747P mutant exhibited resistance to gefitinib and erlotinib, it remained sensitive to second-generation TKIs like afatinib and dacomitinib.
Figure 1. To test drug sensitivity, researchers created Ba/F3 cells with the EGFR-L747P mutant. They examined the effects of gefitinib, erlotinib, afatinib, and dacomitinib on these cells, as well as other significant and resistant EGFR mutations, to determine their effectiveness. (Yoshizawa T, et al., 2021)
The Human EGFR-DEL19/T790M Stable Cell Line from Creative Biogene offers a robust platform for studying EGFR mutations. This cell line can facilitate research into the efficacy of novel TKIs and contribute to the development of targeted therapies for uncommon EGFR-mutated lung cancer.
A: Our human EGFR-T790M stable cell line has undergone long-term stability testing and maintains stable expression levels over multiple passages. We regularly validate cell lines and record cell line stability data. Customers can request this data from us to understand the stability performance of our products.
A: Our human EGFR-T790M stable cell line is fully functional and widely used in anticancer drug resistance research. We provide detailed functional verification data, including cell proliferation experiments, cell apoptosis experiments, etc. Customers can refer to these data to evaluate the performance of our products.
A: Our human EGFR-T790M stable cell line has been widely used in anti-tumor drug screening experiments, and relevant literature has been published to support its effectiveness in drug screening. We welcome customers to refer to these documents and provide further experimental support to meet their research needs.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
I used Human EGFR-DEL19/T790M Stable Cell Line - Ba/F3 for experiments and the experience was very satisfactory. This cell line expresses the EGFR-DEL19/T790M mutant and is an important tool for studying EGFR mutations and resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). By expressing this mutant, the Ba/F3 cell line is not only stable but also easy to operate. The supplier's technical support is also very professional. From cell culture to answering technical questions, the entire process was very smooth.
Human EGFR-DEL19/T790M Stable Cell Line - Ba/F3 is an efficient research model, especially suitable for studying the role of EGFR mutants in non-small cell lung cancer and their drug resistance mechanisms. After expressing EGFR-DEL19/T790M, the cells showed a loss of dependence on IL-3 and were able to grow in media without IL-3. This feature makes my experiments easier and more efficient. At the same time, the service provided by the supply platform is also very timely and meticulous. From cell quality to after-sales support, everything is very satisfactory.
Using Human EGFR-DEL19/T790M Stable Cell Line - Ba/F3 for experiments, I felt its advantages as a reliable experimental tool. The expression of the EGFR-DEL19/T790M mutant makes Ba/F3 cells an ideal model for studying EGFR mutations and drug resistance mechanisms in lung cancer. Cell growth is stable and gene expression is consistent, making it particularly suitable for signal transduction and cancer research. The service provided by the supplier was also excellent, and their quick response and professional guidance ensured that my experiment went smoothly.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
